



Associate Prof. Xavier ROSSELLÓ, Spain

Xavier Roselló is an academic clinical cardiologist based in Hospital Universitari Son Espases, Mallorca (Spain). He is also a clinical scientist at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid (Spain), as well as an Associate Professor at the University of the Balearic Islands, Mallorca (Spain) and an Honorary Associate Professor at the London School of Hygiene and Tropical Medicine.

He performed his clinical training at Hospital de la Santa Creu I Sant Pau (Barcelona), his PhD in experimental cardiovascular science at University College London (2017) and his MSc in Medical Statistics at the London School of Hygiene and Tropical Medicine (2018), where he focused on risk scores, survival analyses and randomized clinical trials. He undertook his postdoc at Centro Nacional de Investigaciones Cardiovasculares (CNIC, Madrid, 2018-19).

He has published more than 160 papers (>50% as first, co-first or corresponding author). Among them, around 85% are related to clinical research, whereas the remaining 15% are related to basic or translational research. He has published in The New England Journal of Medicine twice, The Lancet, and the three top Cardiology Journals (e.g, >10 papers in JACC, 8 in EHJ). Among many other commitments, he is the trial coordinator of a large clinical aiming to recruit >8,000 patients (Treatment with Beta-blockers After Myocardial Infarction without Reduced Ejection fraction, or REBOOT trial), and a member (past chairperson) of the Methodology and Stats Committee of the PESA (Progression of Early Subclinical Atherosclerosis) Study. He was the statistician of the Spanish registry for acute heart failure and has developed the MEESI-AHF risk score (Annals of Internal Medicine, 2017).

He is a member of the ESC clinical practice guidelines and the ESC Registries Committee and has been TF coordinator of the 2023 ESC Guidelines for the management of acute coronary syndromes. Moreover, he is a member of the Quality indicators Study Group, and the Acute Heart Failure Study Group of the ACVC.